Industry Rethinking Visual Elements And Quality-Of-Life Claims After US FDA Drug Ad Crackdown

 
• By Sue Sutter
  
Line in the sand
Is the FDA drawing a line in the sand on inappropriate claims? (Shutterstock)

More from Marketing & Advertising

More from Compliance